PASSAGE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
PASSAGE BIO, INC. (PASG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 79.92 thousand shares for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-09-03
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-12-31 was 108.71K shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 69.57K shares, a 97.07% decline from fiscal 2023.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 2.37M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 79.92K shares S-4/A · filed 2026-09-03 | |||
| 2025-12-31 | 0.00 shares derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | 41.29K shares S-4/A · filed 2026-09-03 | ||
| 2025-09-30 | 41.29K shares 10-Q · filed 2025-11-10 | |||
| 2024-12-31 | 69.57K shares 10-K · filed 2025-03-04 | |||
| 2023-12-31 | 108.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | 2.37M shares 10-K · filed 2024-03-04 | ||
| 2023-09-30 | 2.26M shares 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |